Anti PD-L1 monoclonal antibody - Biocad

Drug Profile

Anti PD-L1 monoclonal antibody - Biocad

Alternative Names: Anti PD-L1 mAb ; BCD-135

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocad
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 ligand-1inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 06 Mar 2018 Preclinical trials in Cancer in Russia (unspecified route) (Biocad pipeline, March 2018)
  • 31 Oct 2017 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, First-line therapy, Second-line therapy or greater) in Russia (unspecified route) (NCT03464032)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top